Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 2/20 | 1.00 |
| ▸ | CDK2 | P24941 | 2/20 | 1.00 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 1.00 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 12/20 | 0.66 |
| ▸ | NPC1 | O15118 | 10/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 10/20 | 0.66 |
| ▸ | RAB9A | P51151 | 9/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 9/20 | 0.66 |
| ▸ | HPGD | P15428 | 9/20 | 0.66 |
| ▸ | NPSR1 | Q6W5P4 | 6/20 | 0.66 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.66 |
| ▸ | MAPT | P10636 | 3/20 | 0.66 |
| ▸ | GAA | P10253 | 2/20 | 0.66 |
| ▸ | GLA | P06280 | 1/20 | 0.66 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.59 |
| ▸ | PKM | P14618 | 3/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30874471 | 1.00 | CDK1 (1.00) | CDK1CDK2MKNK1MKNK2ALDH1A1 | |
| SCHEMBL30874496 | 0.83 | CDK1 (0.71) | CDK1CDK2MKNK1MKNK2ALDH1A1 | |
| SCHEMBL30874526 | 0.82 | MKNK1 (0.69) | CDK1CDK2MKNK1MKNK2ALDH1A1 | |
| SCHEMBL30802382 | 0.82 | MKNK1 (0.69) | CDK1CDK2MKNK1MKNK2ALDH1A1 | |
| SCHEMBL26227556 | 0.82 | MKNK1 (0.69) | CDK1CDK2MKNK1MKNK2ALDH1A1 | |
| SCHEMBL2175033 | 0.82 | CDK1 (0.69) | CDK1CDK2MKNK1MKNK2METAP2 | |
| SCHEMBL6530312 | 0.82 | CDK1 (0.69) | CDK1CDK2MKNK1MKNK2ALDH1A1 | |
| SCHEMBL30802417 | 0.82 | CDK1 (0.69) | CDK1CDK2MKNK1MKNK2METAP2 | |
| SCHEMBL9986177 | 0.81 | NPC1 (0.68) | CDK1CDK2MKNK1MKNK2ALDH1A1 | |
| SCHEMBL2191709 | 0.81 | MKNK1 (0.68) | CDK1CDK2MKNK1MKNK2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10844282-B2 | Corrosion inhibiting formulations and uses thereof | KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS (SA) | 2020-11-24 | — | — | US | disclosed |
| US-20200291297-A1 | CORROSION INHIBITING FORMULATIONS AND USES THEREOF | KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS (SA) | 2020-09-17 | — | — | US | disclosed |
| US-9837622-B2 | Metal complexes | MERCK PATENT GMBH (DE) | 2017-12-05 | — | — | US | disclosed |
| US-9837622-B2 | Metal complexes | MERCK PATENT GMBH (DE) | 2017-12-05 | — | — | US | disclosed |
| US-9273080-B2 | Metal complexes | MEREK PATENT GMBH (DE) | 2016-03-01 | — | — | US | disclosed |
| US-20150263297-A1 | Metal Complexes | MERCK PATENT GMBH (DE) | 2015-09-17 | — | — | US | disclosed |
| US-20150263297-A1 | Metal Complexes | MERCK PATENT GMBH (DE) | 2015-09-17 | — | — | US | disclosed |
| CN-101316853-B | Benzothiazole and thiazolopyridine as SIRTUIN modulators | SIRTRIS PHARMACEUTICALS INC | 2014-09-24 | — | — | CN | disclosed |
| WO-2014008982-A1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2014-01-16 | — | — | WO | disclosed |
| US-20130082209-A1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2013-04-04 | — | — | US | disclosed |
| WO-2007019346-A1 | BENZOTHIAZOLES AND THIAZOLOPYRIDINES AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | WO | disclosed |
| WO-2007019346-A1 | BENZOTHIAZOLES AND THIAZOLOPYRIDINES AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | WO | disclosed |
| WO-2007019344-A1 | IMIDAZO [2,1-B] THIAYOLE DERIVATIVES AS SIRTUIN MODULATING COMPOUNDS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | WO | disclosed |
| WO-2007019344-A1 | IMIDAZO [2,1-B] THIAYOLE DERIVATIVES AS SIRTUIN MODULATING COMPOUNDS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | WO | disclosed |
| US-20070037809-A1 | histone deacetylase inhibitors, used for treating preventing diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood disorders, inflammation, cancer, and/or hot flashes | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | US | disclosed |
| US-20070037809-A1 | histone deacetylase inhibitors, used for treating preventing diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood disorders, inflammation, cancer, and/or hot flashes | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | US | disclosed |
| US-20070037809-A1 | histone deacetylase inhibitors, used for treating preventing diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood disorders, inflammation, cancer, and/or hot flashes | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | US | disclosed |
| WO-2007019416-A1 | BENZIMIDAZOLE DERIVATIVES AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | WO | disclosed |
| US-20070037827-A1 | Silent Information Regulators; aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting , increased mitochondrial activity, inflammation, cancer, and/or flushing; increased lifespan specially in mutant sir2 strains; imidazo[1,2-a]pyridine drivatives | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | US | disclosed |
| WO-2007019345-A1 | IMIDAZOPYRIDINE DERIVATIVES AS SIRTUIN MODULATING AGENTS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037827-A1 | Silent Information Regulators; aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting , increased mitochondrial activity, inflammation, cancer, and/or flushing; increased lifespan specially in mutant sir2 strains; imidazo[1,2-a]pyridine drivatives | SIRT2, SIRT1, SIRT3 | CDK1 1344/4885CDK2 961/4885MKNK1 1067/4885 |
| US-20070037809-A1 | histone deacetylase inhibitors, used for treating preventing diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood disorders, inflammation, cancer, and/or hot flashes | SIRT1, SIRT3, SIRT2 | CDK1 1197/4885CDK2 1842/4885MKNK1 763/4885 |
| US-20150263297-A1 | Metal Complexes | SOD1, AP1M1, AP3M1 | CDK1 3238/4885CDK2 2823/4885MKNK1 1655/4885 |
| US-20130082209-A1 | METAL COMPLEXES | MCOLN2, MCOLN1, AP1M1 | CDK1 976/4885CDK2 1297/4885MKNK1 1058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.